A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

568

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
COPD
Interventions
DRUG

indacaterol

Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

DRUG

formoterol

Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.

DRUG

placebo to indacaterol

Placebo TWISTHALER® device

DRUG

placebo to formoterol

Placebo AEROLIZER® device

DRUG

short acting β2- agonist

100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Trial Locations (75)

Unknown

Novartis Investigator site, Buenos Aires

Novartis Investigator Site, Rosario

Novartis Investigator Site, Santillán

Novartis Investigator Site, Liège

Novartis Investigator Site, Santiago

Novartis Investigator Site, Val Pariso

Novartis Investigator Site, Bois-Guillaume

Novartis Investigator Site, Clermot Ferand

Novartis Investigator Site, Lille

Novartis Investigator Site, Marseille

Novartis Investigator Site, Nantes

Novartis Investigator site, Toulouse

Novartis Investigator Site, Berlin

Novartis Investigator site, Bibertal

Novartis Investigator Site, Bochum

Novartis Investigator Site - 2 sites, Bonn

Novartis Investigator Site, Cologne

Novartis Investigator Site, Frankfurt

Novartis Investigator Site, Hamburg

Novartis Investigator Site, Heidelberg

novartis Investigator site, Koblenz

Novartis Investigator Site, Marburg

Novartis Investigator Site, Solingen

Novartis Investigator Site, Budapest

Novartis Investigator Site, Debrecen

Novartis investigator site, Pécs

Novartis investigator site, Dublin

Novartis Investigator Site, Genova

Novartis Investigator Site, Napoli

Novartis Investigator Site, Pordenone

Novartis investigator site, Daugavpils

Novartis Investigator Site, Riga

Novartis Investigator Site, Kaunas

Novartis Investigator Site, Klaipėda

Novartis Investigator Site, Vilnius

Novartis Investigator Site, Tronheim

Novartis Investigator Site, Lima

Novartis Investigator Site, Izabelin

Novartis Investigator Site, Lodz

Novartis Investigator Site, Lublin

Novartis Investigator site, Mrozy

Novartis Investigator Site, Olsztyn

Novartis Investigator Site, Rzeszów

Novartis Investigator Site, Wejhrowo

Novartis Investigator Site, Włocławek

Novartis Investigator Site, Bucharest

Novartis Investigator Site, Cluj-Napoca

Novartis Investigator Site, Iași

Novartis Investigator Site, Timișoara

Novartis Investigator Site, Bloemfontain

Novartis Investigator Site, Bloemfontein

Novartis Investigator Site, Cape Town

Novartis Investigator Site, Durban

Novartis Investigator Site, eManzimtoti

Novartis Investigator Site, George

Novartis Investigator Site, Johannesburg

Novartis Investigator Site, Port Elizabeth

Novartis Investigator Site, Pretoria

Novartis Investigator Site, Tygerberg

Novartis Investigator Site, Erzurum

Novartis Investigator Site, Isparta

Novartis Investigator Site, Istanbul

Novartis Investigator Site, Kahramanmaraş

Novartis Investigator Site, Kayseri

Novartis Investigator Site, Malatya

Novartis Investigator Site, Manisa

Novartis Investigator Site, Sanliurfa

Novartis Investigator Site, Trabzon

Novartis Investigator Site, Belfast

Novartis Investigator Site, Chesterfield

Novartis Investigator Site, Glasgow

Novartis Investigator Site, Plymouth

Novartis Investigator Site, Warminster

Novartis investigator site, Watford

Novartis Investigator Site, Whitstable

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Novartis

INDUSTRY

NCT00557466 - A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter